Trial Profile
A Phase III trial of X-22 for smoking cessation
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 30 Jun 2017
Price :
$35
*
At a glance
- Drugs Nicotine (Primary)
- Indications Smoking withdrawal
- Focus Therapeutic Use
- Sponsors 22nd Century
- 30 Jun 2017 New trial record
- 22 Jun 2017 According to a 22nd Century media release, Center for Drug Evaluation and Research (CDER) of the U.S. FDA and the company will work to design this trial. The company plans to initiate this trial in first half of 2018, subject to funding source.